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with advanced basal cell carcinoma:
final update of the pivotal ERIVANCE
BCC study
Aleksandar Sekulic1*, Michael R. Migden2, Nicole Basset-Seguin3, Claus Garbe4, Anja Gesierich5, Christopher D. Lao6,
Chris Miller7, Laurent Mortier8, Dedee F. Murrell9, Omid Hamid10, Jorge F. Quevedo11, Jeannie Hou12,
Edward McKenna12, Natalie Dimier13, Sarah Williams13, Dirk Schadendorf14, Axel Hauschild15 and for the ERIVANCE
BCC InvestigatorsCorrection to: BMC Cancer
DOI 10.1186/s12885-017-3286-5Following publication of the original article [1], it was
reported that the legend for Fig. 1 was incomplete. The
complete figure legend is:
Fig. 1 Swimlane plot of time to response, treatment
duration, and duration of follow-up for efficacy-evaluable
patients who achieved response in the mBCC cohort
(a), those in the laBCC cohort with treatment duration
> 20months (b), and those in the laBCC cohort who were
treated for < 20months (c). laBCC, locally advanced basal
cell carcinoma; mBCC, metastatic basal cell carcinoma.
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